From the PR "The CytoGenix synDNA(TM) technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron. "The first order of synDNA(TM) met and exceeded our expectations in terms of quality, cost, and turn-around time."
I guess the order for Aldevron NEVER happened? CYGX never got payment? No revenue for 2006?
Hello?????
Knock knock knock!!
Arnold?
You stop your speculation. It is happeneing. With Aldevron.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.